SCHEMBL30775263

SCHEMBL30775263

c1ccc(CCNc2cc(OC3CCNC3)ncn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.44
HTR2C P28335 3/20 0.43
HTR2B P41595 3/20 0.43
PRCP P42785 1/20 0.42
HRH4 Q9H3N8 2/20 0.40
HRH3 Q9Y5N1 2/20 0.40
HRH2 P25021 1/20 0.40
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
KIT P10721 1/20 0.37
ACHE P22303 1/20 0.37
MAP2K7 O14733 2/20 0.37
HRH1 P35367 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775284 0.82 HRH4 (0.46) HRH4HRH3HRH2
SCHEMBL30775286 0.80 HRH4 (0.43) HRH4HRH3HRH2
SCHEMBL1774575 0.78 HRH4 (0.65) HTR7PRCPHRH4HRH3HRH2
SCHEMBL4789931 0.78 HRH4 (0.65) HTR7PRCPHRH4HRH3HRH2
SCHEMBL1775427 0.78 HRH4 (0.65) HTR7PRCPHRH4HRH3HRH2
SCHEMBL30775327 0.76 CHRM1 (0.39) HRH4HRH3HRH2KCNH2
SCHEMBL30775427 0.73 NPC1 (0.49) HTR2CHTR2BHRH1SLC6A2SLC6A4
SCHEMBL5046732 0.68 TDO2 (0.41) HTR7SLC6A2SLC6A3
SCHEMBL2269304 0.68 CHRNB2 (0.53) HTR2CHTR2BHRH1SLC6A2
SCHEMBL2264859 0.68 CHRNB2 (0.53) HTR2CHTR2BHRH1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR HTR7 2745/4885HTR2C 3501/4885HTR2B 2289/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR HTR7 2745/4885HTR2C 3501/4885HTR2B 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.